MedEthix leverages the synergy of strategic alliances to ease Molnupiravir access

This strategy comes amidst the widespread, unprecedented impact of COVID-19 in many countries.

The impact of COVID-19 has been widespread, with its magnitude affecting the stability of social, economic, and political structures in many countries. It has particularly challenged national healthcare systems and their capacity to respond to large-scale outbreaks.

Filipino pharmaceutical company MedEthix went beyond its way as the first importer to secure, through its first 4 hospital partners, from the Food and Drug Administration the compassionate special permit (CSP) for Molnupiravir – an oral drug indicated for mild to moderate cases of COVID-19 infection, which then enabled the standard-of-care to go beyond the confines of the over-stretched hospital wards, into the comforts of the patient’s home.

MedEthix further expanded the distribution of Molnupiravir from the first 4 CSP grantees to over 80 health institutions and over 500 doctors as it successfully secured the Emergency Use Authorisation from the regulatory authority. The expanded access to affordable alternative treatment for COVID-19 benefited the Filipinos during the pandemic.

“MedEthix has recognised the needs of the Filipinos during the pandemic and has responded through the importation of Molnupiravir. We are also proud to note that we made the first shipment in Southeast Asia” said Monaliza Salian, President and CEO of MedEthix.

The advent of COVID-19, coming as it did exactly 100 years after the Spanish Influenza outbreak, caught the world by surprise. For MedEthix, as a supply chain value enabler, COVID-19 presented not only an opportunity to leverage its partnerships and optimise its internal resources and network, thus, addressing the healthcare needs of the Filipinos.

The company’s capability in providing an end-to-end pharma supply chain solution has been recognised by the Healthcare Asia Pharma Awards as it takes home the Hospital Partnership of the Year - Philippines and the Most Differentiated Service of the Year - Philippines for this venture.

The prestigious awards programme honours outstanding pharma companies in Asia that have demonstrated unwavering commitment to innovation and excellence and have redefined pharmaceutical excellence.

The Healthcare Asia Pharma Awards is presented by Healthcare Asia Magazine. To view the full list of winners, click here. If you want to join the 2025 awards programme and be recognised for your organisation's innovative and unique initiatives that enhanced your business and remarkable contributions to the pharmaceutical industry, please contact Julie Anne Nuñez at [email protected].